Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer-Reference-Cited by-同舟云学术

Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer

Published:2015-12-24 Issue:4 Volume:7 Page:4925-4938
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Takahashi Naoki¹,Furuta Koh²,Taniguchi Hirokazu³,Sasaki Yusuke¹,Shoji Hirokazu¹,Honma Yoshitaka¹,Iwasa Satoru¹,Okita Natsuko¹,Takashima Atsuo¹,Kato Ken¹,Hamaguchi Tetsuya¹,Shimada Yasuhiro¹⁴,Yamada Yasuhide¹

Affiliation:

1. Division of Gastrointestinal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

2. Division of Clinical Laboratories, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

3. Division of Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

4. Division of Clinical Oncology, Kochi Health Sciences Center, 2125-1 Ike, Koch-city, Koch, 781-8555, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies;Cancers;2024-08-15

2. Targeting MET amplification in Gastro-oesophageal (GO) malignancies and overcoming MET inhibitor resistance: challenges and opportunities;Expert Review of Gastroenterology & Hepatology;2022-06-30

3. Current status and future perspectives in HER2 positive advanced gastric cancer;Clinical and Translational Oncology;2022-01-29

4. The drugs screened by OncoVee^TM-Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer;Journal of Oncology Pharmacy Practice;2022-01-24

5. Establishment of a prognostic model of ten transcription factors in gastric cancer;Genomics;2021-11